



HIV VACCINES:

Fitting them into the Prevention Conversation

S.F. Wakefield

Director, Community Relations
HIV Vaccine Trials Network

HIV Prevention – What Works?



- Barrier protection
- Blood screening
- IDU harm reduction
- STI Treatment?
- Antiretroviral Therapy
 - PMTCT
 - Rx infected partners

DECREASE SOURCE OF INFECTION

DECREASE HOST SUSCEPTIBILITY


- Barrier protection
- Infection Control
- Circumcision
- Vaccines?
- STI Treatment?
- PEP
- Oral PREP
- Topical microbicides

ALTER BEHAVIOR

- Condom and HIV testing promotion
- Individual interventions
- Couples interventions
- Community-based interventions
- Structural interventions (e.g., economic)



Key Clinical Trial Milestones: HIV Vaccine Research




The HIV Vaccine Trials Network is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases.



HIV VACCINE
TRIALS NETWORK



NIAID Survey



Assessing the Attitudes,
Knowledge, and Awareness
of HIV Vaccine Research
Among Adults in the United
States

M. Allen et al.

Telephone Survey by
NIAID's HIV Vaccine
Communications
Campaign of 2,000
members of the general
population and 500 each
of African Americans,
Hispanics, and MSM in
selected U.S. cities



HIV VACCINE
TRIALS NETWORK

Results of NIAID Survey

- Majority of respondents across groups believe an HIV vaccine is the best way to control and end the global AIDS epidemic
- People believe that an HIV vaccine already exists and is being kept a secret
 - 47.1% African-Americans
 - 26.5% Hispanics
 - 13.4% MSM
- Many incorrectly believed that the HIV vaccines being tested could cause HIV or they didn't know if they could
 - 78% African-Americans
 - 57.5% Hispanics
 - 68% MSM



Racial Differences in HIV-Related Beliefs

	Black MSM (n=239) %	Latino MSM (n=152) %	HIV/AIDS Conspiracy Belief
Pharmaceutical companies hiding cure for HIV/AIDS for profits	58*	50*	42
HIV/AIDS drugs do more harm than help you			41
HIV does not cause AIDS			27
HIV is a man-made virus	30	41	35

High levels of mistrust are associated with

- not testing for HIV;
- not taking HIV medication;
- and missing routine clinical care visits


**P*<.05 versus White MSM

(Hutchinson, 2007)



WHO IS THE HVTN?

The HVTN has conducted 60 clinical studies supporting the evaluation of 43 HIV-1 vaccine candidates. Collaborating with over 125 institutions worldwide we continue to demonstrate a commitment to answer those questions raised by every study through providing specimens, sharing data, developing assays and other scientific endeavors. Trial participants make it possible for the scientific community to determine next steps with each product tested.




The HIV Vaccine Trials Network is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases.



HIV VACCINE
TRIALS NETWORK

HIV Prevalence Among U.S. Black MSM Compared to Countries with Generalized Epidemics



Colfax, 2011 Adapted from: El-Sadr, et al., *NEJM*, 2010



HIV VACCINE
TRIALS NETWORK